Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SRZN

Surrozen Inc

May 10 • 01:19PM ET

10.12

Dollar change -0.11
Percentage change -1.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DCOR DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-14.01	Insider Own	39.89%	Shs Outstand	2.06M	Perf Week	1.20%
Market Cap	32.38M	Forward P/E	-	EPS next Y	-3.15	Insider Trans	43.52%	Shs Float	1.92M	Perf Month	-8.71%
Income	-37.58M	PEG	-	EPS next Q	-2.79	Inst Own	30.42%	Short Float	2.15%	Perf Quarter	15.66%
Sales	0.00M	P/S	-	EPS this Y	44.35%	Inst Trans	44.36%	Short Ratio	2.41	Perf Half Y	60.67%
Book/sh	14.30	P/B	0.71	EPS next Y	73.46%	ROA	-67.75%	Short Interest	0.04M	Perf Year	8.17%
Cash/sh	8.53	P/C	1.19	EPS next 5Y	29.90%	ROE	-80.66%	52W Range	4.50 - 16.19	Perf YTD	7.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-123.77%	52W High	-37.49%	Beta	0.87
Dividend TTM	-	Quick Ratio	5.18	Sales past 5Y	-33.33%	Gross Margin	77.27%	52W Low	124.89%	ATR (14)	0.93
Dividend Ex-Date	-	Current Ratio	5.18	EPS Y/Y TTM	27.22%	Oper. Margin	0.00%	RSI (14)	48.34	Volatility	6.65% 9.69%
Employees	42	Debt/Eq	0.09	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	33.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-788.70%	Payout	-	Rel Volume	2.00	Prev Close	10.23
Sales Surprise	-	EPS Surprise	0.24%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	17.16K	Price	10.12
SMA20	4.66%	SMA50	-12.20%	SMA200	10.16%	Trades		Volume	21,979	Change	-1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-11-21	Initiated	BofA Securities	Buy	$11
Sep-15-21	Initiated	Guggenheim	Buy	$20
Sep-07-21	Initiated	Stifel	Buy	$19

May-09-24 08:30AM	Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
May-08-24 11:55PM	SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Surrozen Provides First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-03-24 08:40AM	Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis (GlobeNewswire) +13.41%
08:30AM	Loading…
Apr-01-24 08:30AM	Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -35.71%
08:30AM	Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 (GlobeNewswire)
Jan-18-24 09:58AM	Surrozen stops IBD program due to dose concerns and competition (FierceBiotech.com) -5.53%
08:30AM	Surrozen Provides Corporate Update on Clinical Programs (GlobeNewswire)
Dec-14-23 05:52AM	SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023 (InvestorPlace) +9.33%
05:51AM	SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023 (InvestorPlace)
Nov-08-23 04:05PM	Surrozen Provides Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 04:05PM	Surrozen Provides Second Quarter 2023 Financial Results (GlobeNewswire) +5.52%
Jun-05-23 08:30AM	Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke (GlobeNewswire)
May-10-23 04:05PM	Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates (GlobeNewswire)
08:30AM	Loading…
Apr-05-23 08:30AM	Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt (GlobeNewswire)
Mar-28-23 04:59AM	Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-22-23 04:01PM	Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress (GlobeNewswire)
Mar-20-23 04:30PM	Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023 (GlobeNewswire)
Jan-04-23 04:41PM	Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-22 04:30PM	Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-10-22 08:00AM	Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week (GlobeNewswire)
Oct-06-22 08:00AM	Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases (GlobeNewswire)
Sep-26-22 08:00AM	Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy (GlobeNewswire)
Aug-11-22 08:00AM	Surrozen Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-27-22 10:34AM	What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)? (Simply Wall St.)
Jun-13-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis (GlobeNewswire)
May-24-22 08:00AM	Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) (GlobeNewswire) -5.75%
May-18-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis (GlobeNewswire) +7.29%
May-16-22 08:00AM	Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD) (GlobeNewswire)
08:00AM	Loading…
May-11-22 08:00AM	Surrozen Reports First Quarter 2022 Financial Results (GlobeNewswire) -8.74%
May-05-22 08:00AM	Surrozen to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire) -12.88%
May-02-22 08:00AM	Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Mar-24-22 08:00AM	Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -6.03%
Jan-20-22 09:00AM	Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share (GlobeNewswire) -7.62%
Jan-10-22 08:00AM	Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline (GlobeNewswire)
Jan-05-22 08:00AM	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-21 04:00PM	Surrozen Reports Third Quarter 2021 Financial Results (GlobeNewswire)
08:00AM	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
08:00AM	Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-11-21 10:51AM	How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own? (Simply Wall St.) +19.50%
Nov-05-21 08:00AM	Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference (GlobeNewswire)
Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week (GlobeNewswire) -5.75%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources (GlobeNewswire) -9.07%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration (GlobeNewswire)

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COLUMN GROUP III GP, LP	10% Owner	Apr 04 '24	Buy	15.50	193,548	2,999,994	332,885	Apr 08 04:23 PM
Kutzkey Tim	Director	Apr 04 '24	Buy	15.50	193,548	2,999,994	332,885	Apr 08 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRZN

Surrozen Inc

Upgrade your FINVIZ experience